Early zoledronate treatment inhibits subchondral bone microstructural changes in skeletally-mature, ACL-transected canine knees

Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling

“…Zoledronic acid (zoledronate) is one of the preferred drugs for OP treatment [ 30 ]. Animal experiments focusing on OA have shown that zoledronate exhibits a partial effect on cartilage proteins, thereby enhancing the local osteochondral barrier and maintaining the thickness of subchondral and cancellous bones [ 31 ]. These findings hold significance for the treatment of OA.…”